Document:

Exhibit 4.1

 

	
	CLASS A SHARE CERTIFICATE
HONG KONG SHARE REGISTER
DATE OF ISSUE CERTIFICATE NUMBER RUN/TFR. NO. REGISTER NUMBER OF SHARE(S)
CODE:
NUMBER OF SHARE(S):
GIVEN UNDER THE SECURITIES SEAL OF THE COMPANY ON THE DATE OF ISSUE STATED ABOVE.
DIRECTOR
NO TRANSFER OF THE WHOLE OR ANY PORTION OF THE ABOVE SHARE(S) CAN BE REGISTERED UNLESS ACCOMPANIED BY THIS SHARE CERTIFICATE.
HONG KONG SHARE REGISTRAR: COMPUTERSHARE HONG KONG INVESTOR SERVICES LIMITED, SHOPS 1712-1716, 17TH FLOOR, HOPEWELL CENTRE, 183 QUEEN’S ROAD EAST, WANCHAI, HONG KONG.
THIS IS TO CERTIFY THAT THE UNDERMENTIONED PERSON(S) IS/ARE THE REGISTERED HOLDER(S) OF FULLY PAID CLASS A
ORDINARY SHARE(S) OF NOMINAL VALUE US$0.00005 PER SHARE IN THE SHARE CAPITAL OF TUYA INC. (THE “COMPANY”)
AS DETAILED BELOW SUBJECT TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY.
Tuya Inc.
(A company controlled through weighted voting rights and incorporated in the Cayman Islands with limited liability)
V1.1Exhibit
10.4

 

STOCK
PURCHASE AGREEMENT

 

THIS
STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of March 15, 2021, is entered into between Vivacitas
Oncology Inc., with a business address at 1990 N. California Boulevard 8th Floor Walnut Creek, CA 94596 (the “Seller”),
and SeD BioMedical International, Inc., a wholly owned subsidiary of Impact BioMedical Inc. and an indirect wholly owned subsidiary
of Document Security Systems, Inc., a business address at 200 Canal View Blvd, Suite 104 Rochester, NY14623 (the
“Buyer”).

 

WHEREAS,
Buyer wishes to purchase from Seller Five Hundred Thousand (500,000) shares of the common stock, $0.0001 par value (the “Shares”),
of Vivacitas Oncology Inc., a Nevada corporation (the “Company”); and

 

WHEREAS,
Seller wishes to sell to Buyer the Shares, subject to the terms and conditions set forth herein;

 

NOW,
THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.
Purchase and Sale. Subject to the terms and conditions set forth herein, at the Closing (as defined in Section 2), Seller
shall sell to Buyer, and Buyer shall purchase from Seller the Shares. The aggregate purchase price for the Shares at the value of $1.00
per share shall be Five Hundred Thousand U.S. Dollars ($500,000) (the “Purchase Price”).

 

2.
Closing. Subject to the terms and conditions contained in this Agreement, the purchase and sale of the Shares contemplated hereby
shall take place at a closing (the “Closing”) to be held at within Fourteen (14) Business Days of the execution of
this Agreement by both Buyer and Seller (the “Closing Date”) at the offices of the Company, or at such other place
or on such other date as Buyer and Seller may mutually agree upon in writing, and/or electronically. At the Closing, Seller shall deliver
to Buyer or its nominee a stock certificate or certificates evidencing the Shares, free and clear of all Encumbrances (as defined herein),
duly endorsed in blank or accompanied by stock powers or other instruments of transfer duly executed in blank, and Buyer shall deliver
to Seller the Purchase Price no later than Fourteen (14) Business Days after the Closing Date (i) by check or (ii) by wire transfer of
immediately available funds to the following account:

 

	 	Company: 	Vivacitas
Oncology, Inc.
	 	 	 
	 	Bank:	Bank of America 
	 	 	 
	 	Routing:
	026009593
	 	 	 
	 	Account:	2910-1610-4408
	 	 	 
	 	Address:	1900
N. California Boulevard, 8th Floor
	 	 	Walnut Creek, CA 94596
	 	 	 
	 	Telephone:	708-710-9200
	 	 	 
	 	Bank Address: 	203
N LaSalle St. Lobby G1
	 	 	Chicago, IL 60601

 

    	 	Initials: __/__

     

    

 

3.
Closing Conditions.

 

(a)
The obligation of Seller to sell, transfer and assign the Shares to Buyer or its nominee hereunder is subject to the satisfaction of
the following conditions as of the Closing:

 

(i)
the representations and warranties of Buyer in Section 5 hereof shall be true and correct on and as of the Closing Date with the
same effect as though made at and as of such date; and

 

(ii)
Buyer shall have performed and complied in all material respects with all agreements and conditions required by this Agreement to be
performed or complied with by it prior to or on the Closing Date.

 

(b)
The obligation of Buyer to purchase the Shares from Seller is subject to the satisfaction of the following conditions as of the Closing:

 

(i)
the representations and warranties of Seller in Section 4 shall be true and correct on and as of the Closing Date with the same
effect as though made at and as of such date; and

 

    	 	2	Initials: __/__

     

    

 

(ii)
Seller shall have performed and complied in all material respects with all agreements and conditions required by this Agreement to be
performed or complied with by it prior to or on the Closing Date.

 

(iii)
Seller shall deliver to Buyer Board Resolutions approving this Agreement, the appointment of Mark Suseck as CEO and the allocation of
two (2) board seats prior to the Closing Date for Mark Suseck and Heng Fai Ambrose Chan. Board appointments are for three (3) year terms
and limited to no more than two (2) consecutive terms.

 

(iv)
Seller shall deliver to Buyer the Share Certificate prior to or on the Closing Date.

 

4.
Representations and Warranties of Seller. Seller hereby represents and warrants to Buyer as follows:

 

(a)
Seller has all requisite power and authority to execute and deliver this Agreement, to carry out his obligations hereunder, and to consummate
the transactions contemplated hereby. This Agreement has been duly executed and delivered by Seller and (assuming due execution and delivery
by Buyer) constitutes Seller’s legal, valid and binding obligation, enforceable against Seller in accordance with its terms.

 

(b)
The Shares have been duly authorized, are validly issued, fully paid and non-assessable, and are owned of record and beneficially by
Seller, free and clear of all liens, pledges, security interests, charges, claims, encumbrances, agreements, options, voting trusts,
proxies and other arrangements or restrictions of any kind (“Encumbrances”). Upon consummation of the transactions
contemplated by this Agreement, Buyer shall own the Shares, free and clear of all Encumbrances.

 

(c)
The execution, delivery and performance by Seller of this Agreement do not conflict with, violate or result in the breach of, or create
any Encumbrance on the Shares pursuant to, any agreement, instrument, order, judgment, decree, law or governmental regulation to which
Seller is a party or is subject or by which the Shares are bound.

 

(d)
No governmental, administrative or other third party consents or approvals are required by or with respect to Seller in connection with
the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby.

 

(e)
There are no actions, suits, claims, investigations or other legal proceedings pending or, to the knowledge of Seller, threatened against
or by Seller that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement.

 

    	 	3	Initials: __/__

     

    

 

(f)
No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the
transactions contemplated by this Agreement based upon arrangements made by or on behalf of Seller.

 

(g)
Seller covenants to appoint Mark Suseck as CEO.

 

(h)
Buyer shall be allocated two (2) seats on the Board of Directors, which initially shall be Mark Suseck and Heng Fai Ambrose Chan.

 

(i)
As of March 11th, 2021, the authorized capital stock of the Seller consisted of 40,000,000 shares of Common Stock, par value $0.0001
per share, and 0 shares of preferred stock, par value $0.0001 per share. As of March 11th, 2021, there were 18,930,164 shares of Common
Stock and 0 shares of preferred stock, issued and outstanding. As of March 11th, 2021, there were 250,000 shares of Common Stock reserved
for issuance pursuant to the Sellers’s outstanding options and warrants, 10,330,000 shares of Common Stock reserved pursuant to
the Seller’s option plans, and 0 shares reserved for conversion of the Sellers’s outstanding convertible or exchangeable
securities.

 

5.
Representation and Warranties of Buyer.

 

(a)
Buyer is a corporation in the United States.

 

(b)
Buyer has all requisite power and authority to enter into this Agreement, to carry out its obligations hereunder and to consummate the
transactions contemplated hereby. The execution and delivery by Buyer of this Agreement, the performance by Buyer of its obligations
hereunder and the consummation by Buyer of the transactions contemplated hereby have been duly authorized by all requisite action on
the part of Buyer. This Agreement has been duly executed and delivered by Buyer and (assuming due execution and delivery by Seller) this
Agreement constitutes a legal, valid and binding obligation of Buyer enforceable against Buyer in accordance with its terms.

 

(c)
Buyer is acquiring the Shares solely for its own account for investment purposes and not with a view to, or for offer or sale in connection
with, any distribution thereof. Buyer acknowledges that the Shares are not registered under the Securities Act of 1933, as amended, or
any state securities laws, and that the Shares may not be transferred or sold except pursuant to the registration provisions of the Securities
Act of 1933, as amended or pursuant to an applicable exemption therefrom and subject to state securities laws and regulations, as applicable.

 

    	 	4	Initials: __/__

     

    

 

(d)
There are no actions, suits, claims, investigations or other legal proceedings pending or, to the knowledge of Buyer, threatened against
or by Buyer that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement.

 

(e)
No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the
transactions contemplated by this Agreement based upon arrangements made by or on behalf of Buyer.

 

6.
Option for Additional Investment. The Seller hereby grants to the Buyer the option to purchase up to an additional One Million
Five Hundred Thousand (1,500,000) shares of the Seller’s common stock at a price of $1.00 per share, in one or more transactions,
at any time until the option terminates. The option will terminate upon one of the following events: (i) The Seller’s board of
directors cancels this option because it is no longer in the best interest of the Company; (ii) December 31, 2021; or (iii) the date
on which the Seller receives more than $1.00 per share of the Company’s common stock in a private placement with gross proceeds
of at least $500,000.

 

7.
Survival. All representations and warranties contained herein shall survive the execution and delivery of this Agreement and the
Closing hereunder.

 

8.
Indemnification. Seller shall indemnify Buyer and hold Buyer harmless against and in respect of any and all losses, liabilities,
damages, obligations, claims, Encumbrances, costs and expenses (including, without limitation, reasonable attorneys’ fees) incurred
by Buyer resulting from any breach of any representation, warranty, covenant or agreement made by Seller herein.

 

9.
Further Assurances. Following the Closing, each of the parties hereto shall execute and deliver such additional documents, instruments,
conveyances and assurances, and take such further actions as may be reasonably required to carry out the provisions hereof and give effect
to the transactions contemplated by this Agreement.

 

10.
Expenses. All costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be
paid by the party incurring such costs and expenses.

 

11.
Entire Agreement. This Agreement constitutes the sole and entire agreement of the parties to this Agreement with respect to the
subject matter contained herein, and supersedes all prior and contemporaneous understandings, agreements, representations and warranties,
both written and oral, with respect to such subject matter.

 

    	 	5	Initials: __/__

     

    

 

12.
Successor and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective
successors and permitted assigns. No party may assign any of its rights or obligations hereunder, except to a subsidiary of Document
Security Systems, Inc., without the prior written consent of the other parties hereto, which consent shall not be unreasonably withheld
or delayed.

 

13.
Headings. The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.

 

14.
Amendment and Modification; Waiver. This Agreement may only be amended, modified or supplemented by an agreement in writing signed
by each party hereto. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing
and signed by the party so waiving. Except as otherwise set forth in this Agreement, no failure to exercise, or delay in exercising,
any rights, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof.

 

15.
Severability. If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity,
illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such
term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable,
the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely
as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated
to the greatest extent possible.

 

16.
Governing Law. This Agreement shall
be governed by and construed in accordance with the internal laws of the State of New York without giving effect to any choice or conflict
of law provision or rule (whether of the State of New York or any other jurisdiction).

 

17.
Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed
to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, email or other means of electronic transmission
shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	 	6	Initials: __/__

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement on the date first written above.

 

	 	Vivacitas
    Oncology, Inc.
	 	 	 
	 	By: 	 
	 	Name:	Scott VanderMeer
	 	Title:	Interim Chief Financial
    Officer
	 	Date:	3/15/2021
	 	      	 
	 	SeD BioMedical
    International, Inc.
	 	 	 
	 	By: 	 
	 	Name:	Frank D. Hueszel
	 	Title:	Chief Executive Officer
	 	Date:	3/15/21

 

    	 	7	Initials: __/__

     

    

 

EXHIBIT
A

 

Vivacitas
Oncology Inc.

 

Capitalization
Table

 

	Equity Holders	 	Common Stock	 	 	Vested Options	 	 	Non-Vested Options	 	 	Fully Diluted

                                                                                # of Shares

                                                                                outstanding
	 	 	Fully Diluted Percentages	 
	Infusion 51a LP	 	 	15,121,164	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	51.24	%
	Heng Fai Enterprise Pte LTD	 	 	2,480,000	 	 	 	250,000	 	 	 	 	 	 	 	 	 	 	 	9.25	%
	Liam McMorrow	 	 	450,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1.52	%
	Rosa Grasso-Solomon	 	 	350,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1.19	%
	Brian Harvey	 	 	200,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.68	%
	Priya Kumthekar	 	 	100,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.34	%
	John Brugmann	 	 	100,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.34	%
	Elise Brownell	 	 	80,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.27	%
	Peter Seperack	 	 	25,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.08	%
	Darien Group, LLC	 	 	15,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.05	%
	Stefan Proniuk	 	 	9,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.03	%
	Employee Stock Options	 	 	 	 	 	 	 	 	 	 	10,330,000	 	 	 	 	 	 	 	35.00	%
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total Shares	 	 	18,930,164	 	 	 	250,000	 	 	 	10,330,000	 	 	 	29,510,164	 	 	 	100	%

 

    	 	8	Initials: __/__

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]